Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Engineering a multilayered thin-film agarose-based hydrogel to support adipose-derived stromal vascular fraction therapy in spinal cord injury.

Veneruso V., Giorgi Z., Petillo E., Frigerio E., Pizzetti F., Roato I.

Animal Study on Spinal Cord Injury, Chronic Inflammation, published in Int J Biol Macromol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Biol Macromol (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42190778
DOI
10.1016/j.ijbiomac.2026.152683

Abstract (original English)

Acute spinal cord injury (SCI) remains a devastating neurological condition with limited therapeutic options. While cell therapy using adipose-derived stromal vascular fraction (SVF) represents a promising approach, effective delivery strategies are critical for clinical success. To address this challenge, this study introduces an innovative therapeutic platform based on a multi-layered thin-film hydrogel, specifically engineered to optimize SVF cell delivery and functionality. By overcoming the critical limitations of traditional bulk hydrogels-such as restricted nutrient diffusion and heterogeneous cell distribution-this layered architecture ensures a uniform cellular microenvironment throughout the three-dimensional space. To further enhance biological performance, an extracellular matrix (ECM) pre-deposition strategy was implemented. By pre-coating the hydrogel layers with SVF-derived ECM, a highly supportive niche was established that significantly promotes cell adhesion and prolonged viability compared to naïve scaffolds. In vivo assessments using intravital microscopy in an SCI model demonstrated the superior efficacy of this system. Specifically, the layered hydrogel successfully preserved SVF viability for extended periods, marking a significant improvement over direct intraparenchymal injections, which resulted in rapid cell degeneration. Furthermore, the hydrogel con

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Spinal Cord InjuriesAnimalsHydrogelsAdipose TissueSepharoseStromal Vascular FractionExtracellular MatrixTissue EngineeringHumansTissue Scaffolds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research